Who is the CEO of Abliva AB (publ)?

The CEO of Abliva AB (publ) is Ellen K. Donnelly.

What industry does Abliva AB (publ) belong to?

Abliva AB (publ) operates in the Biotechnology industry within the Healthcare sector.

Where is Abliva AB (publ) headquartered?

Abliva AB (publ) is headquartered at Medicon Village, Lund, 223 81, SE.

What is the IPO date of Abliva AB (publ)?

Abliva AB (publ) went public on March 20, 2014.

How many employees does Abliva AB (publ) have?

Abliva AB (publ) has approximately 6 full-time employees.

Abliva AB (publ)

NEVPF•PNK

Healthcare

Biotechnology

$0.03

$0.00(0.00%)

Abliva AB (publ) (NEVPF) Company Profile & Overview

Explore Abliva AB (publ)’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

Abliva AB (publ) (NEVPF) Company Profile & Overview

Abliva AB (publ) develops medicines for the treatment of primary mitochondrial diseases. The company is developing KL1333 that is in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT that is in Phase 1b/2a clinical study for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.

SectorHealthcare

IndustryBiotechnology

CEOEllen K. Donnelly

Contact Information

https://abliva.com

46 4 62 75 62 20

Medicon Village, Lund, 223 81

Company Facts

6 Employees

IPO DateMar 20, 2014

CountrySE

Frequently Asked Questions

;